Finally, resected lung cancer patients, in stage IB-IIIA NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, can now benefit from adjuvant osimertinib after EMA approval in May 2021, based on the results of the ADAURA trial [5] (Figure 1). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.